Literature DB >> 25496247

Diversion of methadone and buprenorphine from opioid substitution treatment: patients who regularly sell or share their medication.

Björn Johnson1, Torkel Richert.   

Abstract

Diversion-the practice of patients selling or sharing their medication-is a much debated problem of opioid substitution treatment. Regular diversion by patients was studied at 11 opioid substitution treatment programs in the south of Sweden. Using quantitative and qualitative data, it was investigated whether those patients differ from other patients, their motives for and means of diversion, and who the recipients are. Regular diverters are a small, yet heterogeneous group. Continued illicit drug use, however, stands out as a common risk factor. Pecuniary need and a desire to help friends are other important motives. The client base mainly consists of people from the regular diverters' own drug milieus.

Entities:  

Keywords:  Methadone; buprenorphine; diversion; illicit use; opioid substitution treatment

Mesh:

Substances:

Year:  2015        PMID: 25496247     DOI: 10.1080/10550887.2014.975617

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  10 in total

1.  Increasing diversion of methadone in Vancouver, Canada, 2005-2015.

Authors:  Hudson Reddon; Joel Ho; Kora DeBeck; M-J Milloy; Yang Liu; Huiru Dong; Keith Ahamad; Evan Wood; Thomas Kerr; Kanna Hayashi
Journal:  J Subst Abuse Treat       Date:  2017-11-28

2.  Prescription Opioid Misuse Motives in US Older Adults.

Authors:  Ty S Schepis; Linda Wastila; Beth Ammerman; Vita V McCabe; Sean Esteban McCabe
Journal:  Pain Med       Date:  2020-10-01       Impact factor: 3.750

3.  "People need them or else they're going to take fentanyl and die": A qualitative study examining the 'problem' of prescription opioid diversion during an overdose epidemic.

Authors:  Geoff Bardwell; Will Small; Jennifer Lavalley; Ryan McNeil; Thomas Kerr
Journal:  Soc Sci Med       Date:  2021-05-03       Impact factor: 5.379

4.  Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden.

Authors:  Torkel Richert; Björn Johnson
Journal:  Harm Reduct J       Date:  2015-02-18

5.  Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.

Authors:  Björn Johnson; Torkel Richert
Journal:  Harm Reduct J       Date:  2019-05-02

6.  Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.

Authors:  Eugenia Oviedo-Joekes; Scott MacDonald; Charles Boissonneault; Kelli Harper
Journal:  Subst Abuse Treat Prev Policy       Date:  2021-03-05

7.  Development of an Emergency Department-Based Intervention to Expand Access to Medications for Opioid Use Disorder in a Medicaid Nonexpansion Setting: Protocol for Engagement and Community Collaboration.

Authors:  Lauren A Walter; Li Li; Erik P Hess; Joel B Rodgers; Jennifer J Hess; Rachel M Skains; Matthew C Delaney; James Booth
Journal:  JMIR Res Protoc       Date:  2021-04-29

8.  Buprenorphine Dosage and Urine Quantitative Buprenorphine, Norbuprenorphine, and Creatinine Levels in an Office-Based Opioid Treatment Program.

Authors:  Hiroko Furo; Diane G Schwartz; Ross W Sullivan; Peter L Elkin
Journal:  Subst Abuse       Date:  2021-12-06

9.  Therapy without a prescription: buprenorphine/naloxone diversion and the therapeutic assemblage in Taiwan.

Authors:  Jia-Shin Chen
Journal:  Sociol Health Illn       Date:  2019-12-13

Review 10.  Misalignment of Stakeholder Incentives in the Opioid Crisis.

Authors:  Alireza Boloori; Bengt B Arnetz; Frederi Viens; Taps Maiti; Judith E Arnetz
Journal:  Int J Environ Res Public Health       Date:  2020-10-16       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.